To ensure that these glycan requirements for lectin-inhibition are relevant to the realities of disease progression and virus evolution, we conducted infection inhibition assays with several variants of SARS-CoV-2 pseudoviruses and CV-N, the most potent of the lectins we tested (Figure ). While CV-N produced dose-dependent inhibition against all of the variants tested, it was most effective against the most recent variant tested, Omicron.